Pan-lysyl oxidase inhibition disrupts fibroinflammatory tumor stroma, rendering cholangiocarcinoma susceptible to chemotherapy.

Autor: Burchard PR; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Ruffolo LI; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Ullman NA; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Dale BS; Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA., Dave YA; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Hilty BK; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Ye J; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Georger M; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Jewell R; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Miller C; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., De Las Casas L; Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA., Jarolimek W; Drug Discovery, Syntara Ltd., Sydney, New South Wales, Australia., Perryman L; Drug Discovery, Syntara Ltd., Sydney, New South Wales, Australia., Byrne MM; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Loria A; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Marin C; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Chávez Villa M; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Yeh JJ; Departments of Surgery and Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina System, Chapel Hill, North Carolina, USA., Belt BA; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA., Linehan DC; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA.; Department of Surgery, Division of Surgical Oncology, University of Rochester Medical Center, Rochester, New York, USA., Hernandez-Alejandro R; Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA.; Division of Solid Organ Transplant Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA.

Publikováno v: Hepatology communications [Hepatol Commun] 2024 Aug 05; Vol. 8 (8). Date of Electronic Publication: 2024 Aug 05 (Print Publication: 2024).

A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer.

Autor: Chitty JL; Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.; School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, UNSW Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia., Yam M; Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Perryman L; Pharmaxis, Frenchs Forest, New South Wales, Australia., Parker AL; Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.; School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, UNSW Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia., Skhinas JN; Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Setargew YFI; Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Mok ETY; Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Tran E; Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Grant RD; Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Latham SL; School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, UNSW Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Pereira BA; School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, UNSW Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Ritchie SC; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Murphy KJ; School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, UNSW Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Trpceski M; School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, UNSW Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Findlay AD; Pharmaxis, Frenchs Forest, New South Wales, Australia., Melenec P; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Filipe EC; Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.; School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, UNSW Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia., Nadalini A; Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Velayuthar S; Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Major G; Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Wyllie K; Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Papanicolaou M; Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Ratnaseelan S; Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Phillips PA; School of Biomedical Sciences, Faculty of Medicine, Lowy Cancer Research Centre, UNSW Sydney, Sydney, New South Wales, Australia., Sharbeen G; School of Biomedical Sciences, Faculty of Medicine, Lowy Cancer Research Centre, UNSW Sydney, Sydney, New South Wales, Australia., Youkhana J; School of Biomedical Sciences, Faculty of Medicine, Lowy Cancer Research Centre, UNSW Sydney, Sydney, New South Wales, Australia., Russo A; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Blackwell A; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Hastings JF; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Lucas MC; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Chambers CR; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Reed DA; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Stoehr J; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Vennin C; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Pidsley R; School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, UNSW Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Zaratzian A; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Da Silva AM; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Tayao M; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Charlton B; Pharmaxis, Frenchs Forest, New South Wales, Australia., Herrmann D; Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.; School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, UNSW Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia., Nobis M; School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, UNSW Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.; Intravital Imaging Expertise Center, VIB Center for Cancer Biology, VIB, Leuven, Belgium., Clark SJ; School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, UNSW Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Biankin AV; Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK., Johns AL; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Croucher DR; School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, UNSW Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Nagrial A; Department of Medical Oncology, Westmead Hospital, Sydney, New South Wales, Australia., Gill AJ; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.; NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, Sydney, New South Wales, Australia.; Cancer Diagnosis and Pathology Research Group, Kolling Institute of Medical Research, Sydney, New South Wales, Australia., Grimmond SM; University of Melbourne Centre for Cancer Research, VCCC, Melbourne, Victoria, Australia., Pajic M; School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, UNSW Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.; The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia., Timpson P; Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.; School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, UNSW Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia., Jarolimek W; Pharmaxis, Frenchs Forest, New South Wales, Australia. wolfgang.jarolimek@pharmaxis.com.au., Cox TR; Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia. t.cox@garvan.org.au.; School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, UNSW Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia. t.cox@garvan.org.au.

Publikováno v: Nature cancer [Nat Cancer] 2023 Sep; Vol. 4 (9), pp. 1326-1344. Date of Electronic Publication: 2023 Aug 28.

Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3

Autor: Findlay, AD, Foot, JS, Buson, A, Deodhar, M, Jarnicki, AG, Hansbro, PM, Liu, G, Schilter, H, Turner, CI, Zhou, W, Jarolimek, W

Copyright © 2019 American Chemical Society. Lysyl oxidase-like 2 (LOXL2) is a secreted enzyme that catalyzes the formation of cross-links in extracellular matrix proteins, namely, collagen and elastin, and is indicated in fibrotic diseases. Herein,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______363::d49b97746263414fcaa13b95790e86cf
https://hdl.handle.net/10453/136757

Topical application of an irreversible small molecule inhibitor of lysyl oxidases ameliorates skin scarring and fibrosis.

Autor: Chaudhari N; Burn Injury Research Unit, School of Biomedical Sciences, The University of Western Australia, Crawley, Australia.; School of Molecular Sciences, The University of Western Australia, Crawley, Australia., Findlay AD; Drug Discovery Department, Pharmaxis Ltd, Sydney, NSW, Australia., Stevenson AW; Burn Injury Research Unit, School of Biomedical Sciences, The University of Western Australia, Crawley, Australia., Clemons TD; School of Molecular Sciences, The University of Western Australia, Crawley, Australia.; School of Polymer Science and Engineering, University of Southern Mississippi, Hattiesburg, MS, 39406, USA., Yao Y; Drug Discovery Department, Pharmaxis Ltd, Sydney, NSW, Australia., Joshi A; Drug Discovery Department, Pharmaxis Ltd, Sydney, NSW, Australia., Sayyar S; Intelligent Polymer Research Institute, Australian Research Council Centre of Excellence for Electromaterials Science, University of Wollongong, Wollongong, NSW, 2500, Australia.; Australian National Fabrication Facility-Materials Node, Innovation Campus, University of Wollongong, Wollongong, NSW, 2500, Australia., Wallace G; Intelligent Polymer Research Institute, Australian Research Council Centre of Excellence for Electromaterials Science, University of Wollongong, Wollongong, NSW, 2500, Australia.; Australian National Fabrication Facility-Materials Node, Innovation Campus, University of Wollongong, Wollongong, NSW, 2500, Australia., Rea S; Burns Service of Western Australia, WA, Department of Health, Nedlands, WA, Australia., Toshniwal P; Burn Injury Research Unit, School of Biomedical Sciences, The University of Western Australia, Crawley, Australia., Deng Z; Burn Injury Research Unit, School of Biomedical Sciences, The University of Western Australia, Crawley, Australia., Melton PE; Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.; School of Pharmacy and Biomedical Sciences, Curtin University, Bentley, WA, Australia.; School of Global Population Health, University of Western Australia, Crawley, Australia., Hortin N; Burn Injury Research Unit, School of Biomedical Sciences, The University of Western Australia, Crawley, Australia., Iyer KS; School of Molecular Sciences, The University of Western Australia, Crawley, Australia., Jarolimek W; Drug Discovery Department, Pharmaxis Ltd, Sydney, NSW, Australia., Wood FM; Burn Injury Research Unit, School of Biomedical Sciences, The University of Western Australia, Crawley, Australia.; Burns Service of Western Australia, WA, Department of Health, Nedlands, WA, Australia., Fear MW; Burn Injury Research Unit, School of Biomedical Sciences, The University of Western Australia, Crawley, Australia. mark.fear@uwa.edu.au.

Publikováno v: Nature communications [Nat Commun] 2022 Sep 22; Vol. 13 (1), pp. 5555. Date of Electronic Publication: 2022 Sep 22.

Neurological phenotype and synaptic function in mice lacking the Ca V1.3 α subunit of neuronal L-type voltage-dependent Ca 2+ channels

Autor: Clark, N.C, Nagano, N, Kuenzi, F.M, Jarolimek, W, Huber, I, Walter, D, Wietzorrek, G, Boyce, S, Kullmann, D.M, Striessnig, J, Seabrook, G.R

Publikováno v: In Neuroscience 2003 120(2):435-442